The FDA's approval of $BIIB's Aduhelm is spurring major backlash in the scientific community — most notably, with the resignations of 3 advisers to the agency. The question now is whether lawmakers, payers and patients will balk. With @PamBelluck: https://t.co/DSzzLiNBtG
@RebeccaDRobbins@PamBelluck “Giving patients a drug that doesn’t work and of course has important risks that are going to require multiple MRIs at a price of $56,000 a year is putting patients in a really challenging position and putting doctors in a difficult position as well,” Dr. Kesselheim said.
@RebeccaDRobbins@PamBelluck After the advisory committee makes a reccomendation, who at the FDA actually approves the drug? Is it a committee or a single person? Is there a vote that is on record? Is there a way to investigate financial incentives?